Chelsea Meyer, DO
Neurology · Saint Joseph, MONPI 1417368986
Payments from drug & device makers
Across 109 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$500
- EMD Serono, Inc.$181
- UCB, Inc.$133
- Eisai Inc.$95
- Teva Pharmaceuticals USA, Inc.$83
- Novartis$68
- plus $800 from 25 others
What the payments were for
- Speaking & faculty fees$402%
- Food & beverage$1,82198%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $500 |
| EMD Serono, Inc. | 10 | $181 |
| UCB, Inc. | 7 | $133 |
| Eisai Inc. | 5 | $95 |
| Teva Pharmaceuticals USA, Inc. | 6 | $83 |
| Novartis | 3 | $68 |
| Johnson & Johnson | 4 | $64 |
| Lundbeck LLC | 3 | $60 |
| AstraZeneca | 3 | $55 |
| Abbott | 3 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Sanofi | 3 | $45 |
| Lilly USA, LLC | 3 | $43 |
| Acorda Therapeutics, Inc | 3 | $40 |
| GE HealthCare | 3 | $40 |
| Kyowa Kirin, Inc. | 2 | $34 |
| Argenx US, Inc. | 1 | $34 |
| Microtransponder, Inc. | 1 | $33 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Impel Pharmaceuticals Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Biogen | 1 | $21 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Neurelis, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Adamas Pharmaceuticals, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Catalyst Pharmaceuticals, Inc. | 1 | $15 |
| Livanova USA, Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
How this compares
$1,861 in reported general payments places this provider in the 50th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 16 | $2,637 |
| Memantine Hcl | 34 | $551 |
| Levetiracetam | 15 | $330 |
| Gabapentin | 33 | $239 |
| Donepezil Hcl | 34 | $237 |
| Nortriptyline Hcl | 18 | $188 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Joseph
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Curtis SchreiberBolivar$6.4M
- Gregory WuSaint Louis$5.7M
- Siddharth KaulBridgeton$5.7M
- Kenneth SharlinOzark$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.